A few weeks ago, GEDII‘s annual IBD conference, Portugal’s premier event for inflammatory bowel disease (IBD) specialists, brought together leading gastroenterologists and researchers from across Europe. The conference, attended by approximately 200 Portuguese GI and IBD doctors, featured presentations on the latest advancements in IBD treatment.
Among the esteemed speakers was Dr. Prof. Shomron Ben Horin, MD, co-founder of Evinature, who presented findings from recent placebo-controlled trials on the efficacy of CurQD®. His research highlighted CurQD®’s growing role in evidence-based natural supplement protocols for gastrointestinal conditions and its potential to complement conventional therapies.
Reflecting on the event, Dr. Ben Horin emphasized the importance of global collaboration in advancing IBD treatment:
“GEDII is an outstanding congress that brings together some of the brightest minds in IBD research. It was a privilege to present our latest CurQD® trial findings to an engaged audience of Portuguese gastroenterologists and international experts. The discussions were dynamic, and it’s clear there is a growing interest in integrating natural, evidence-based solutions into clinical practice.”
The GEDII Congress continues to be a vital platform for advancing IBD research and fostering international collaboration. Evinature remains committed to pioneering natural, science-backed solutions for gastrointestinal health, with CurQD® at the forefront of innovation.
Evinature
